TABLE 3.
Projected Probabilities of Ever Recovering a Normal CD4% Within 4 Years, by WHO Immunodeficiency Classification and Agea,b
| Baseline WHO Immune Deficiency Classification | Age at HAART Initiation | Overallc n = 162 % (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| 0 to <1 y n = 26 % (95% CI) | 1 to <3 y n = 19 % (95% CI) | 3 to <5 y n = 24 % (95% CI) | 5 to <8 y n = 38 % (95% CI) | 8 to <13yr n = 38 % (95% CI) | 13 to <18 y n = 17 % (95% CI) | ||
| Mild, n = 31 | 97 (88% to 100%) | 96 (88% to 100%) | 96 (87% to 100%) | 95 (86% to 100%) | 93 (82% to 100%) | 91d (76% to 100%) | 95 (86% to 100%) |
| Advanced, n = 40 | 95 (75% to 100%) | 92 (74% to 100%) | 86 (72% to 100%) | 80 (68% to 92%) | 70 (53% to 86%) | 56 (27% to 85%) | 80 (68% to 92%) |
| Severe, n = 91 | 83 (69% to 98%) | 77 (65% to 90%) | 69 (59% to 78%) | 59 (50% to 68%) | 44 (31% to 56%) | 22 (0% to 44%) | 59 (50% to 68%) |
| Overall,e n = 162 | 94 (83% to 100%) | 88 (79% to 97%) | 80 (73% to 86%) | 70 (64% to 77%) | 56 (46% to 65%) | 35 (18% to 52%) | 71 (65% to 77%) |
a
Additive Poisson regression estimates; adjusted for age, gender, race, and interaction between WHO Immunologic Classification and age; estimated at the covariate distribution of primary outcome subset.
b
Wald upper 95% confidence limits exceeding 100% were rounded to 100%.
c
Overall WHO category estimates are at the primary endpoint subset mean age (6.3 y).
d
n = 0 for this cell.
e
Overall age estimates are adjusted for gender and race only.